Platelet Membrane-Coated Nanoparticles Sebagai Sistem Penghantaran Aspirin Daninhibitor P2Y12 Pada Penatalaksanaan Infark Miokard Akut : A Literature Review

Muhammad Rifqi Al Azim; Fawwaz M Virajati; Saminur Muzaqi; Muhammad Althariq Huda

doi:10.62027/vitamedica.v4i3.911

Authors

Muhammad Rifqi Al Azim Universitas Andalas
Fawwaz M Virajati Universitas Andalas
Saminur Muzaqi Universitas Negeri Padang
Muhammad Althariq Huda Universitas Baiturrahmah

DOI:

https://doi.org/10.62027/vitamedica.v4i3.911

Keywords:

acute myocardial infarction, platelet membrane-coated nanoparticles, aspirin, P2Y12 inhibitors, biomimetic nanoparticles

Abstract

Background: Acute myocardial infarction (AMI) is a severe manifestation of coronary artery disease, commonly caused by atherosclerotic plaque rupture and thrombus formation. Dual antiplatelet therapy with aspirin and P2Y12 inhibitors is a cornerstone of AMI management but remains limited by bleeding risk and nonspecific drug distribution. Platelet membrane-coated nanoparticles (PM-NPs) are biomimetic drug delivery systems with potential for targeted therapy. Objective: To review the potential of PM-NPs for delivering aspirin and P2Y12 inhibitors in AMI management. Methods: A literature review was conducted using PubMed, ScienceDirect, and Google Scholar with the keywords “platelet membrane-coated nanoparticles,” “aspirin,” “P2Y12,” and “acute myocardial infarction.” Articles published within the last 10 years, available in full text, and written in English or Indonesian were selected according to predefined criteria. Twelve relevant articles were identified after screening. Results: PM-NPs demonstrated potential for targeting thrombi, atherosclerotic plaques, and injured myocardial tissue. They may improve drug stability, circulation time, and targeted delivery while reducing oxidative stress, inflammation, and ischemia-reperfusion injury. However, evidence regarding combined aspirin and P2Y12 inhibitor delivery remains limited and predominantly preclinical. Conclusion: PM-NPs represent a promising targeted antithrombotic platform for AMI. Further studies are required to establish the safety and efficacy of combined aspirin and P2Y12 inhibitor delivery.

References

Brannon, E. R., Piegols, L. D., Cady, G., Kupor, D., Chu, X., Guevara, M. V., Lima, M. R. N., Kanthi, Y., Pinsky, D. J., Uhrich, K. E., & Eniola-Adefeso, O. (2025). Polymerized Salicylic Acid Microparticles Reduce the Progression and Formation of Human Neutrophil Extracellular Traps (NET)s. Advanced Healthcare Materials, 14(5), 2400443. https://doi.org/10.1002/ADHM.202400443

Chen, Y., Lin, L., Xu, L., Jin, Q., Fu, W., Bai, Y., Huang, T., Gao, T., Wu, W., Xu, C., Wang, J., Zhang, L., Lv, Q., Yang, Y., Xie, M., & Dong, X. (2025). Platelet-mimicking nanoparticles loaded with diallyl trisulfide for Mitigating Myocardial Ischemia-Reperfusion Injury in rats. Colloids and Surfaces. B, Biointerfaces, 248. https://doi.org/10.1016/J.COLSURFB.2024.114460

Franchi, F., Schneider, D. J., Prats, J., Fan, W., Rollini, F., Been, L., Taatjes-Sommer, H. S., Bhatt, D. L., Deliargyris, E. N., & Angiolillo, D. J. (2022). Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study. Journal of Thrombosis and Thrombolysis, 54(3), 373–381. https://doi.org/10.1007/S11239-022-02687-5/FIGURES/4

Ghavimi, M. A., Bani Shahabadi, A., Jarolmasjed, S., Memar, M. Y., Maleki Dizaj, S., & Sharifi, S. (2020). Nanofibrous asymmetric collagen/curcumin membrane containing aspirin-loaded PLGA nanoparticles for guided bone regeneration. Scientific Reports 2020 10:1, 10(1), 18200-. https://doi.org/10.1038/s41598-020-75454-2

Guo, X., Hong, T., Zang, J., Shao, R., Hou, X., Wang, K., Liu, W., Su, F., & He, B. (2022). Thrombus-specific/responsive biomimetic nanomedicine for spatiotemporal thrombolysis and alleviation of myocardial ischemia/reperfusion injury. Journal of Nanobiotechnology, 20(1). https://doi.org/10.1186/S12951-022-01686-1

Han, H., Bártolo, R., Li, J., Shahbazi, M. A., & Santos, H. A. (2022). Biomimetic platelet membrane-coated nanoparticles for targeted therapy. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik e.V, 172, 1–15. https://doi.org/10.1016/J.EJPB.2022.01.004

Ji, M., Tang, Q., Olatunji, O. Y., Ge, R., Ying, Y., Pan, J., Yunusov, K. E., & Jiang, G. (2025). Platelet membrane-camouflaged bioactive glass nano-formulations for enhanced drug delivery in the treatment of acute arterial thrombosis. Acta Biomaterialia, 199, 324–336. https://doi.org/10.1016/J.ACTBIO.2025.04.036

Karam, M., Fahs, D., Maatouk, B., Safi, B., Jaffa, A. A., & Mhanna, R. (2022). Polymeric nanoparticles in the diagnosis and treatment of myocardial infarction: Challenges and future prospects. Materials Today. Bio, 14. https://doi.org/10.1016/J.MTBIO.2022.100249

Liu, H., Su, Y. Y., Jiang, X. C., & Gao, J. Q. (2022). Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system. Drug Delivery and Translational Research 2022 13:3, 13(3), 716–737. https://doi.org/10.1007/S13346-022-01252-0

Park, J. H., Jiang, Y., Zhou, J., Gong, H., Mohapatra, A., Heo, J., Gao, W., Fang, R. H., & Zhang, L. (2021). Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs. Science Advances, 7(25). https://doi.org/10.1126/SCIADV.ABF7820/ASSET/BE489537-CEEE-40AC-B825-ADF24A0B88C7/ASSETS/GRAPHIC/ABF7820-F5.JPEG

Pradhan, A., Tiwari, A., Caminiti, G., Salimei, C., Muscoli, S., Sethi, R., & Perrone, M. A. (2022). Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status. International Journal of Environmental Research and Public Health, 19(15). https://doi.org/10.3390/IJERPH19158977

Song, Y., Huang, Z., Liu, X., Pang, Z., Chen, J., Yang, H., Zhang, N., Cao, Z., Liu, M., Cao, J., Li, C., Yang, X., Gong, H., Qian, J., & Ge, J. (2019). Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE−/−) mice. Nanomedicine: Nanotechnology, Biology and Medicine, 15(1), 13–24. https://doi.org/10.1016/J.NANO.2018.08.002

Su, T., Huang, K., Ma, H., Liang, H., Dinh, P. U., Chen, J., Shen, D., Allen, T. A., Qiao, L., Li, Z., Hu, S., Cores, J., Frame, B. N., Young, A. T., Yin, Q., Liu, J., Qian, L., Caranasos, T. G., Brudno, Y., … Cheng, K. (2019). Platelet-Inspired Nanocells for Targeted Heart Repair After Ischemia/Reperfusion Injury. Advanced Functional Materials, 29(4). https://doi.org/10.1002/ADFM.201803567

Wang, B., Chen, G., Urabe, G., Xie, R., Wang, Y., Shi, X., Guo, L. W., Gong, S., & Kent, K. C. (2018). A paradigm of endothelium-protective and stent-free anti-restenotic therapy using biomimetic nanoclusters. Biomaterials, 178, 293–301. https://doi.org/10.1016/J.BIOMATERIALS.2018.06.025

Wang, S., Duan, Y., Zhang, Q., Komarla, A., Gong, H., Gao, W., & Zhang, L. (2020). Drug Targeting via Platelet Membrane-Coated Nanoparticles. Small Structures, 1(1), 2000018. https://doi.org/10.1002/SSTR.202000018

Wang, S., Wang, R., Meng, N., Guo, H., Wu, S., Wang, X., Li, J., Wang, H., Jiang, K., Xie, C., Liu, Y., Wang, H., & Lu, W. (2020). Platelet membrane-functionalized nanoparticles with improved targeting ability and lower hemorrhagic risk for thrombolysis therapy. Journal of Controlled Release : Official Journal of the Controlled Release Society, 328, 78–86. https://doi.org/10.1016/J.JCONREL.2020.08.030

Wei, Q., Xiao, Y., Du, L., & Li, Y. (2024). Advances in Nanoparticles in the Prevention and Treatment of Myocardial Infarction. Molecules 2024, Vol. 29, Page 2415, 29(11), 2415. https://doi.org/10.3390/MOLECULES29112415

Yaman, S., Chintapula, U., Rodriguez, E., Ramachandramoorthy, H., & Nguyen, K. T. (2020). Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy. Cancer Drug Resist 2020;3:879-911., 3(4), 879–911. https://doi.org/10.20517/CDR.2020.55

Zhang, Z., Chen, Z., Yang, L., Zhang, J., Li, Y., Li, C., Wang, R., Wang, X., Huang, S., Hu, Y., Shi, J., & Xiao, W. (2022). Platelet Membrane–Encapsulated MSNs Loaded with SS31 Peptide Alleviate Myocardial Ischemia-Reperfusion Injury. Journal of Functional Biomaterials, 13(4), 181. https://doi.org/10.3390/JFB13040181/S1

Zhao, Y., Xie, R., Yodsanit, N., Ye, M., Wang, Y., Wang, B., Guo, L. W., Kent, K. C., & Gong, S. (2021). Hydrogen peroxide-responsive platelet membrane-coated nanoparticles for thrombus therapy. Biomaterials Science, 9(7), 2696–2708. https://doi.org/10.1039/D0BM02125C

Zhou, X., Angiolillo, D. J., & Ortega-Paz, L. (2022). P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention. Journal of Cardiovascular Development and Disease, 9(10), 340. https://doi.org/10.3390/JCDD9100340/S1

Zhu, C., Ma, J., Ji, Z., Shen, J., & Wang, Q. (2021). Recent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders. Molecules, 26(11), 3428. https://doi.org/10.3390/MOLECULES26113428.